sustained-release coating: Process Controls and CGMP in Oral Solid Dose Manufacturing
How release-controlling films connect formulation intent, coating operations, dissolution performance and the evidence needed for informed quality decisions.

On this page · 11 sections
- 1What sustained-release coating means
- 2US drug CGMP and product-specific specifications
- 3Coating variables and demonstrated operating ranges
- 4Execute the coating lifecycle with defined checkpoints
- 5Build a traceable coating batch record
- 6Scale-up and transfer: preserve process meaning
- 7Worked reasoning: coating mass and interrupted spraying
- 8Connect systems and recover exceptions without losing context
- 9Follow coating performance through stability
- 10Failure modes: observations, hypotheses and controls
- 11Implementation and batch-review checklist
How does Sustained-Release Coating apply to your shop floor?
Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.
01What sustained-release coating means
Sustained-release coating is a functional film applied to an oral solid dosage unit or drug-containing particle to slow drug release over an extended period. The term describes the film’s formulation role, rather than a universal legal definition or a particular release schedule.
The coated substrate may be a tablet, pellet, bead or suitable granule. In multiparticulate capsule fills, the release-controlling film can surround individual drug-containing particles rather than the capsule itself. Depending on the formulation, fluid enters through the film or its pores, dissolves drug within the substrate, and enables dissolved drug to move outward. Film permeability, pore structure and substrate properties can influence that transport. These are formulation-dependent mechanisms: not every sustained-release coating controls release in the same way.
| Term | Main release intent | Location of control | Important boundary |
|---|---|---|---|
| Sustained-release or extended-release coating | Prolong drug release | Film surrounding the substrate | Shared intent does not establish interchangeable specifications. |
| Controlled-release terminology | Describe deliberately regulated release | Depends on dosage-form design | The term alone does not establish a constant release rate. |
| Delayed-release or enteric coating | Delay release until relevant conditions are met | Condition-responsive film | A delay before release is not necessarily prolonged release afterward. |
| Sustained-release matrix | Prolong drug release | Within the dosage structure | Release control is not necessarily provided by an external film. |
| Protective or cosmetic film | Protect the substrate or change appearance | Outer film | An ordinary film is not necessarily release-controlling. |
These distinctions describe industry usage; product-specific nomenclature takes precedence. When identifying the coating’s function, distinguish its intended role from demonstrated product performance. A release-related critical quality attribute concerns the finished product’s performance, not merely the presence of a film. Neither the coating name nor its appearance establishes dissolution acceptance; use the approved product specification rather than a generic profile associated with the terminology.
02US drug CGMP and product-specific specifications
This regulatory mapping covers US finished human drugs under 21 CFR Part 211. Other jurisdictions, supplements, foods, devices and chemicals are outside its scope. For sustained-release coating, distinguish the legal control framework from the product-specific instructions and criteria used to execute and assess a batch.
Binding law
Within the same binding framework, 21 CFR 211.110(a) calls for written in-process control procedures covering tests or examinations of appropriate in-process-material samples drawn from each batch; see blend uniformity and stratified sampling for how that provision is applied to powder-blend and dosage-unit sampling.
For US finished human drugs under 21 CFR Part 211, 21 CFR 211.110(b) requires valid in-process specifications for the relevant characteristics to be consistent with final drug product specifications. Do not use these provisions as a substitute for a product-specific dissolution profile, polymer level, sampling schedule or acceptance limit.
Official guidance
Keep guidance recommendations separately identified from binding provisions. When applying guidance to a coating operation, identify its product and jurisdictional scope rather than treating an operational recommendation as a legal obligation.
Industry practice and product-specific documents
In product-specific control practice, three linked documents answer different questions:
- The coating instruction describes execution: what operators do and which process settings and checkpoints apply.
- The analytical method describes measurement: how samples are tested and results calculated.
- The approved product specification supplies dissolution acceptance criteria: how the measured results are judged.
These documents serve complementary purposes; a coating endpoint is not a replacement for dissolution acceptance. Dissolution results describe performance under the specified test conditions. They are not, by themselves, a direct measurement of clinical duration.
Software support
Treat an electronic batch record as support for controlled execution and review, not as a source of acceptance criteria or an assurance of compliance. Human review, approval and release remain human decisions. The later batch-record and stability sections address evidence traceability and performance over time, respectively.
03Coating variables and demonstrated operating ranges
In formulation and process-development practice, sustained-release coating controls connect material behaviour and equipment conditions to the film produced. Organise the assessment around four groups rather than treating the coating recipe as a list of independent settings.
| Group | Product-specific assessment |
|---|---|
| Substrate attributes | Core size distribution, surface condition and moisture can affect available surface area, wetting and adhesion. |
| Coating-dispersion attributes | Solids content, viscosity and homogeneity influence dry-material delivery, atomisation and consistency of the applied composition. |
| Equipment conditions | Airflow, exhaust conditions, nozzle arrangement, bed loading, and fluidisation or pan movement influence drying and exposure to spray. |
| Film outcomes | Assess continuity, adhesion and permeability in relation to the intended release performance; appearance alone does not establish these properties. |
Evaluate coupled conditions, not isolated settings
Liquid spray rate describes dispersion delivery, not dry-solids delivery. At the same liquid mass flow, changing the solids mass fraction changes the dry-solids input. Atomisation affects droplet formation; product movement distributes exposure; drying capacity determines how rapidly liquid can leave the wetted surfaces. These interactions are central to understanding the film coating process, because changing one setting can alter the balance between wetting and drying.
Inlet-air temperature describes the incoming air, not the product temperature. A recorded temperature setpoint is an instruction to the control system; the measured response shows what the sensor detected at its location. Interpret both alongside airflow, exhaust behaviour and product movement. These are candidates for assessment, not a universal list of critical process parameters.
Use range terminology precisely
A process variable is a quantity that can change during coating. A demonstrated operating range has supporting evidence for acceptable operation under stated conditions. A parameter identified as critical has a product-specific assessment connecting its variability to quality and the need for control. Separate acceptable ranges do not establish acceptable combinations: use design space only for a defined, supported multivariable relationship, not as another name for recipe limits.
Where relevant to the film system, include conditioning or curing. Some polymer films continue coalescing or changing physically after spraying ends, so subsequent temperature, humidity and handling conditions belong in the product-specific process understanding.
04Execute the coating lifecycle with defined checkpoints
A typical coating workflow uses checkpoints to connect material readiness, equipment conditions and batch handover. The sequence below is an adaptable manufacturing pattern, not a universal procedure: actual stages, responsibilities and checkpoints depend on the established product process.
- Confirm instructions and materials. The production operator records the effective instruction revision and checks core and coating-material identities against the batch assignment. Link the checks to the batch identifier in the paper or electronic batch record.
- Reconcile the core load. The loading operator records the core lot, quantity issued, quantity loaded and any retained or returned material. Resolve unexplained differences through the site's established process before treating the load as ready.
- Prepare and identify the dispersion. The preparer records ingredient lots, preparation sequence and times, vessel identity and mixing status. Identify the dispersion for its intended batch and check its preparation history and applicable hold conditions before use.
- Confirm equipment configuration. The setup operator records the coater identity, nozzle configuration and sensor status, linking relevant setup checks to the batch. Include the dispersion delivery path and agitation arrangement in the readiness check.
- Establish conditions, then spray and monitor. The coating operator records readiness against the defined process conditions before spraying. During coating, connect observations, process readings and interventions to their times and batch stage rather than recording only a final machine status.
- Complete drying or conditioning. Where the process defines these stages, the operator records their conditions and completion evidence. Identify any subsequent holding conditions before moving the coated material.
- Sample and hand over. The designated sampler records sample identity, collection stage and destination. Production hands over the execution evidence; the laboratory associates results with those samples. MES-to-LIMS integration is one implementation pattern for maintaining that association.
The same binding framework addresses disposition through 21 CFR 211.110(c): in-process materials need suitable identity, strength, quality and purity testing, with the quality control unit deciding approval or rejection; capsule weight control discusses this disposition step for a different in-process measurement.
Operational completion and evidence-review completion are separate checkpoints. A practical handover identifies outstanding results, unresolved observations and the person responsible for each follow-up. Quality receives that review status; a completed coater cycle is not a quality decision.
- Confirm instructionsConnect the effective recipe, method and specification.
- Identify materialsLink core and dispersion lots to the batch.
- Establish conditionsRecord equipment configuration and process readiness.
- Apply coatingCapture observations, additions and time-linked events.
- Complete ConditioningFollow the product-specific drying or curing sequence.
- Sample and testConnect representative samples to their run context.
- Review dispositionPresent results and exceptions for authorised assessment.
05Build a traceable coating batch record
For US finished human drugs under 21 CFR Part 211, 21 CFR 211.188 requires production and control records for each batch, including complete information relating to that batch’s production and control.
Required record content
- For US finished human drugs under Part 211, 211.188(a) requires an accurate reproduction of the appropriate master production or control record, checked for accuracy, dated and signed.
- For US finished human drugs under Part 211, 211.188(b)(2)–(3) requires major equipment and line identities and specific identification of each component or in-process material batch used.
- For US finished human drugs under Part 211, 211.188(b)(4)–(5) requires component weights and measures and in-process and laboratory control results.
- For US finished human drugs under Part 211, 211.188(b)(7) requires statements of actual yield and percentage of theoretical yield at appropriate processing phases.
- For US finished human drugs under Part 211, 211.188(b)(11) requires identification of people performing and directly supervising or checking significant steps; for significant steps performed by automated equipment, it requires identification of the person checking the step.
An implementation model, not a prescribed format
A practical electronic batch record model connects batch, material charge, coating run, process event, sample result and quality review through stable identifiers. These are example entities, not legally prescribed database fields.
For coating, link each charge to its material lot and run; link samples and events to that same run. Preserve method and specification versions alongside results so reviewers can interpret the recorded assessment without substituting today’s criteria. Production context tagging supports this association. Link the human quality review to the records assessed, rather than treating a collection of unconnected attachments as the batch history.
Batch
Production identity.
- batch_id
- product_code
- master_record_version
Material Charge
Input genealogy.
- charge_id
- batch_id
- material_lot_id
- quantity
- unit
Coating Run
Execution context.
- run_id
- batch_id
- equipment_id
- recipe_version
Process Event
Time-linked evidence.
- event_id
- run_id
- event_time
- event_type
- source_record_id
Sample result
Analytical context.
- sample_id
- run_id
- method_version
- specification_version
- result_value
- result_unit
Quality Review
Human decision.
- review_id
- batch_id
- reviewer_id
- decision
- decision_time
06Scale-up and transfer: preserve process meaning
In coating technology transfer, equipment is commonly compared by process function, not nominal capacity alone: product circulation, spray exposure, nozzle geometry, airflow distribution and drying behaviour. Copying a spray rate or inlet temperature does not establish equivalent film-forming conditions. The receiving coater may expose material to spray differently or remove moisture differently at the same displayed setting. The useful comparison is how the equipment wets, moves and dries the tablets or particles.
A practical transfer matrix connects each important material attribute or process variable to its original rationale, its representation on the receiving equipment, the measurement method and supporting evidence. For spray delivery, for example, distinguish total delivery from its distribution across nozzles and the bed. Record how that distribution will be assessed. Use product-specific comparisons rather than a universal capacity-based scale factor.
Keep formulation changes, equipment changes and analytical-method transfer distinct within change control. Otherwise, a changed dissolution result can become difficult to interpret. Identify uncertainties explicitly: dispersion handling may differ, temperature sensors may occupy different locations, or sampling access may favour different parts of the bed. Assign an assessment owner to each uncertainty and identify the observation, comparison or study intended to resolve it.
The practical deliverable is an agreed transfer rationale explaining what remains comparable, what changes and what evidence addresses each difference. Technical reviewers can then distinguish supported equivalence from unresolved assumptions, with outstanding assessments assigned to named owners rather than hidden behind matching recipe values.
07Worked reasoning: coating mass and interrupted spraying
Case A: distinguish mass gain from product performance
Assume C is dry core mass in kg, F is final dry coated mass in kg, W is sprayed dispersion mass in kg, and s is dispersion dry-solids fraction in kg/kg. Assume no core loss, no sampling loss, no other solids addition and a consistent dry-mass basis. For this mass balance, the calculations are:
- Deposited coating mass: F − C, in kg.
- Coating-to-core mass ratio: (F − C) / C, in kg/kg.
- Coating fraction of finished solids: (F − C) / F, in kg/kg.
- Applied dry solids: W × s, in kg.
- Apparent deposition efficiency: (F − C) / (W × s), dimensionless.
The denominators answer different questions: C relates coating to the starting cores; F expresses its share of finished solids; W × s compares apparent deposition with sprayed solids. These ratios are not interchangeable. The balance estimates deposited mass and apparent efficiency, not where the coating went on individual units.
Moisture differences or core loss can invalidate a simple mass-gain interpretation; check the drying mass balance before attributing the difference to coating. Average deposited mass does not demonstrate coating uniformity or acceptable dissolution. Use the approved specification identified earlier for acceptance, not an inferred release profile from mass gain.
Case B: assess interrupted spraying despite a passing composite
Assume spraying stops while product movement and drying continue, followed by a restart. A later composite sample meets its approved dissolution specification. No interruption duration or operating limit is assumed.
For this practical assessment, gather event times with time-zone context, liquid spray rate in kg/min, product temperature in degrees Celsius, affected material identity and the applicable interruption instructions. Keep the evidence time-linked so the sequence before, during and after the stop can be reconstructed.
- Reconstruct the affected interval, including continued movement and drying through restart.
- Assess whether the composite sample represents the potentially affected material rather than assuming that its passing result resolves the event.
- Compare actual handling with established interruption instructions.
- Route unresolved uncertainty for authorised assessment through the applicable deviation process.
A passing composite alone does not explain the interrupted process. This reasoning supports a documented human decision, not automatic acceptance or rejection.
08Connect systems and recover exceptions without losing context
For sustained-release coating, the following are manufacturing-system integration patterns, not claims about a particular application. Material systems provide lot identities and quantities; equipment or historians provide time-linked process observations through MES–historian integration. Laboratory systems provide sample, method, specification and result context through MES–LIMS integration. Document systems provide effective instructions, while MES–QMS integration connects exceptions with assessment and decision records. These interfaces commonly connect records without transferring ownership of every underlying decision.
Practical interface checks cover batch and sample identity, units, timestamps, specification version, duplicate messages and rejected transactions. Assign an authoritative owner to each status, such as result approval or material disposition, rather than allowing several systems to overwrite it independently. Reconcile failed exchanges against that owner before treating a receiving system’s display as current.
For a missing historian segment, delayed result or offline entry, preserve the original record and identify the affected batch, interval or sample. Document any reconstruction, including its basis and remaining uncertainty; reconcile duplicates when connectivity returns; and retain the review decision. A reconstructed observation should remain distinguishable from an original measurement. Keep authorised human approval separate from an electronic status transition: successful data transfer is not quality approval, and software support does not establish site compliance.
Once a material is rejected, 21 CFR 211.110(d) calls for a quarantine system that identifies and controls it so it cannot reach manufacturing or processing steps for which it is unsuitable.
In practical status design, distinguish an unresolved-data hold from that rejected-material status. Align physical material handling with the applicable disposition rather than relying only on a screen label.
09Follow coating performance through stability
For US finished human drugs under 21 CFR Part 211, 21 CFR 211.166(a) requires a written testing programme designed to assess drug-product stability characteristics. For those US finished human drugs, 21 CFR 211.166(a)(4) requires the programme to include testing in the same container-closure system in which the drug product is marketed.
In manufacturing practice, sustained-release performance warrants attention because film ageing, moisture interactions or further physical changes can alter transport through the coating. A satisfactory initial dissolution result does not establish that release behaviour will remain unchanged during storage. Assess dissolution using the actual product’s stability programme and approved specification; do not infer a universal dissolution schedule or acceptance profile from the cited provision.
A useful review view commonly brings together stability condition, storage interval, packaging configuration, batch history, analytical method version and observed dissolution behaviour. Keep these attributes connected rather than comparing isolated results stripped of their storage and manufacturing context. Production context tagging provides a practical way to organise those associations within the traceability model described earlier.
Treat a trend as an observation, not an established cause. A shift associated with a packaging configuration or coating history can guide investigation, but does not by itself demonstrate moisture ingress or film change. Review comparability of methods and storage conditions before attributing differences to manufacturing. This keeps product-specific performance assessment separate from hypotheses about the mechanism.
10Failure modes: observations, hypotheses and controls
In coating troubleshooting, an observed defect is a starting point, not a diagnosis. The mechanisms below are provisional and may coexist. Their relevance depends on the product, equipment and event history; physical appearance alone does not establish release performance.
| Observation | Plausible mechanism | Evidence to examine | Control response to assess |
|---|---|---|---|
| Sticking or agglomeration | Possible imbalance between surface wetting and drying | Spray delivery, product temperature, airflow and event history | Assess wetting and drying conditions against established ranges |
| Rough or discontinuous film | Possible premature droplet drying or uneven deposition | Dispersion behaviour, atomisation conditions and film inspection | Assess dispersion preparation and spray conditions |
| Abrasion and fines | Possible attrition during particle movement | Fines location, physical inspection and equipment contact points | Assess movement intensity and contact surfaces |
| Nozzle-related coating asymmetry | Possible uneven spray distribution | Nozzle condition, alignment, spray pattern and deposit location | Assess nozzle cleaning, setup and distribution checks |
| Damage during subsequent handling | Possible impact, friction or compression stress | Samples before and after transfers; handling equipment settings | Assess transfer conditions and protective handling measures |
A practical investigation compares physical inspection and process history with relevant product tests, including dissolution where applicable. Interpret inlet air temperature alongside other drying evidence, rather than as a standalone explanation. Assess proposed adjustments through established process controls and the product-specific critical process parameter assessment; avoid undocumented compensating changes. Record the observation, competing hypotheses, evidence and rationale for the selected response.
11Implementation and batch-review checklist
Use these practical questions to test readiness and evidence usability, not as additional legal requirements.
Readiness
- Is the coating’s intended function explicit?
- Are substrate and dispersion identities traceable to the material used?
- Are the effective instruction, demonstrated operating ranges, analytical method and approved specification connected for this product?
- Are interruption handling, restart decisions and escalation responsibilities defined?
Evidence review
- Using the detailed record discussion above, can a reviewer reconstruct the coating run from its batch execution history?
- Can each sample be related to the relevant material, process stage and events?
- Are units and document versions unambiguous, and can the reviewer locate the assessment of exceptions?
Implementation checks
- Exercise duplicate identifiers, unit mismatches, missing timestamps and interrupted transfers in a controlled test setting.
- Confirm that each exception reaches a named owner and remains visible through assessment in the review-by-exception workflow.
- Confirm that physical material status agrees with the reviewed disposition and that approval and release decisions remain with authorised people.
Frequently asked questions
Q.Is a polymer supplier's technical datasheet enough to predict the finished product's release behaviour?+
No. In formulation practice, a datasheet helps identify candidate materials, but finished-product release also depends on the drug, core structure, film formation, curing and storage. Matching coating weight gain does not establish equivalent film permeability or thickness distribution. A useful assessment combines supplier information with product-specific coating trials and dissolution testing. Comparing representative ingredient lots can also reveal whether lot-to-lot variability affects processing or release. Datasheet values are inputs to that assessment, not substitutes for finished-product performance data.
Q.How should different coated pellet populations be traced when they are blended into one capsule product?+
For US drug products under 21 CFR 211.188, batch records must include complete information relating to each batch's production and control. In practice, give each coated population a distinct identity linked to its core lot, coating operation, curing history and test results. For multiparticulate capsule filling, record the actual quantity of each population entering the blend and link that blend to filled-capsule batches. Preserve these relationships in the batch execution history, including partial transfers and unused balances.
Q.Why can acceptable assay results coexist with atypical dissolution?+
Assay measures drug content; dissolution measures how drug enters solution under defined test conditions. A sustained-release product can therefore contain the expected amount of drug while releasing it differently because of altered film permeability, incomplete curing, cracks or changes in the core. In investigation practice, treat dissolution as a distinct critical quality attribute, rather than inferring it from assay. Assess the dissolution method and sample handling alongside manufacturing history, and evaluate acceptance against the approved product specification.
Q.What additional assessment is useful when coated pellets are compressed into tablets?+
In development practice, assess whether compaction damages the functional film or changes access of dissolution medium to the pellets. Compare pellet performance before compression with performance in the finished tablet using suitable test conditions. Consider compression settings, cushioning excipients, pellet distribution and tablet disintegration. Microscopy can help locate coating defects, but visual appearance alone does not establish release performance. Assessing coating uniformity alongside dissolution helps distinguish pre-existing film variation from damage introduced during tableting.
Q.How should dissolution results with different units or sampling schedules be compared?+
First establish a common reporting basis: concentration, cumulative mass released and percentage released are not interchangeable without supporting calculations. In analytical practice, check medium volume, sample withdrawal and replacement, dilution factors, and the reference amount used for percentage calculations. Align actual sampling times and test conditions before interpreting differences. Do not treat interpolated values as measured observations or assume that unlike methods produce comparable profiles. Preserve original results and documented transformations as part of data integrity.
Q.Can the same coating system provide both enteric protection and sustained release?+
Yes, a formulation can combine both functions, but neither function establishes the other. Enteric protection typically delays release until suitable environmental conditions are reached; sustained release controls the subsequent release rate. Development approaches may use separate functional layers or a combined system. The film coating process assessment should consider layer sequence, adhesion and interactions during curing and storage. Product-specific testing is useful for assessing protection during the initial exposure and release after the intended transition, against the approved specification.
Q.What should be assessed before changing the supplier of a coating-dispersion ingredient?+
A practical supplier risk assessment looks beyond the ingredient name to grade, composition, solids content, viscosity, particle characteristics and relevant impurities. Consider effects on dispersion preparation, spraying, drying, film formation and curing. Through change control, define comparative material and product testing proportionate to the ingredient's function, including dissolution and stability where relevant. Matching purchase specifications alone may not establish functional equivalence. Quality and regulatory reviewers can then assess the evidence and any market-specific implications before approving implementation.
Q.What can placebo-coated development samples demonstrate, and what can they not establish?+
Placebo samples are useful development tools for exploring spray coverage, agglomeration, drying behaviour, film appearance and equipment handling. Within a quality-by-design approach, they can help screen process conditions before working with drug-containing material. Their relevance depends on how closely the placebo matches the intended core's size, porosity, surface and mechanical behaviour. They cannot establish drug release, drug–coating compatibility or drug-product stability. Promising placebo results therefore guide subsequent studies rather than establish performance of the active formulation.
Primary sources
Want to see how Sustained-Release Coating could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.
